Introduction
Accumulation of hyperphosphorylated tau resulting in neurofibrillary tangle formation is one of the established biochemical features of Alzheimer's disease. Tau is a neuron specific, microtubule-associated protein that plays a major role in the assembly and stabilization of microtubules. In the brains of patients with Alzheimer's disease, abnormally phosphorylated tau protein becomes dissociated from neuronal microtubules and accumulates in paired helical filaments, the filamentous network generated by self-aggregation [1] . A growing list of kinases, such as c-jun N-terminal kinase (JNK), glycogen-synthase kinase-3b (GSK3b), and, casein kinase 1 (CK1), have been shown to phosphorylate tau [2] [3] [4] . Immunohistochemical analysis revealed that accumulation of these tau kinases is concomitant with neurofibrillary tangle formation in the hippocampus, and some of these kinases were found to be constituents of granulovacuolar degeneration [2] [3] [4] [5] .
Granulovacuolar degeneration manifests as small inclusions, comprising 3-5-mm-diameter spherical vacuoles surrounded by a halo-like clear zone, which form clusters in the perinuclear region of pyramidal neurons. In addition to senile plaque formation and neurofibrillary tangles, Alzheimer's disease is characterized by granulovacuolar degeneration bodies, which is commonly found in hippocampal pyramidal neurons [6] . Attempts to define the molecular composition of granulovacuolar degeneration granules by immunohistochemical methods have led to the identification of a number of component proteins, suggesting a possible link between granulovacuolar degeneration and Alzheimer's disease-related neurodegeneration. JNK, GSK3b, and CK1, which phosphorylate tau, are also markers of granulovacuolar degeneration [2] [3] [4] . In addition, granulovacuolar degeneration granules are immunopositive for the endosomal sorting complex required for transport (ESCRT)-III subunit, charged multivesicular body protein 2B (CHMP2B) [7, 8] , suggesting that the ESCRT pathway plays a role in granulovacuolar degeneration formation. We previously reported the colocalization of CHMP2B and phosphorylated tau in granulovacuolar degeneration in Alzheimer's disease and other neurodegenerative diseases, suggesting a relationship between the formation of granulovacuolar degeneration bodies and neurofibrillary tangles [9] .
Cyclin-dependent kinase 5 (CDK5) is a serine/threonine kinase that, when activated, induces neurite outgrowth [10, 11] . Unlike most cyclin-dependent kinases, CDK5 functions in differentiated cells [12] . Recent invitro studies have shown that CDK5 phosphorylates tau on Ser202, Thr205, Ser235, and Ser404 [1, 13] . Several studies have identified abundant CDK5 expression in neurofibrillary tangles harbored in hippocampal neurons [14, 15] . Although the granular distribution of CDK5 is indicative of granulovacuolar degeneration, the presence of CDK5 in granulovacuolar degeneration granules has not been clearly demonstrated thus far.
We hypothesized that some CDK5-positive granules in the hippocampus can be attributed to granulovacuolar degeneration. The aim of this study was to examine the pattern of CDK5 immunoreactivity in granulovacuolar degeneration granules with other known granulovacuolar degeneration markers to elucidate the relationship between CDK5, phosphorylated tau and neurofibrillary tangle formation.
Materials and methods
Four cases of Alzheimer's disease, three cases of myotonic dystrophy (MyD) and three control cases were examined ( Table 1 ). The use of human materials conformed to the ethical guidelines of Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan. Autopsies were performed within 24 h. Specimens were fixed in 10% (v/v) formalin for at least 3 weeks, and 7-mm-thick paraffin-embedded sections were prepared for subsequent procedures. All Alzheimer's disease cases met core clinical criteria of new National Institute on Aging and Alzheimer's Association (NIA-AA) criteria [16] and fulfilled the neuropathological criteria for the diagnosis of Alzheimer's disease [Consortium to Establish a Registry for Alzheimer's Disease (CERAD) C] [17] . Alzheimer's disease patients fulfilled the neuropathological criteria for stages V-VI according to the Braak nomenclature [18] . All MyD cases were compatible with clinical features, and the numbers of CTG repeats in the myotonin-protein kinase gene were over 3000. Control cases were free of neurodegenerative disorders, as evidenced by clinical history and confirmed by neuropathological examination. For immunohistochemistry, temporal lobe sections including the temporal isocortex, hippocampus, and entorhinal cortex were used. The primary antibodies used were rabbit polyclonal anti-CDK5 (C-8, dilution 1 : 300; Santa Cruz Biotech, Santa Cruz, California, USA), and anti-CHMP2B (ab33174, dilution 1:600; Abcam, Cambridge, UK), goat polyclonal anti-pSmad2/3 (sc-11769, dilution 1 : 400; Santa Cruz Biotech), mouse monoclonal anti-ubiquitin (Ub, MAB1510, dilution 1 : 2000; Chemicon, Temecula, California, USA), antiphospho-TDP-43 (pS409/410, dilution 1 : 3000; Cosmo Bio Co. Ltd, Tokyo, Japan), and anti-phosphorylated tau (AT8, dilution 1 : 800; Innogenetics, Gent, Belgium).
The sections were deparaffinized and rehydrated. For antigen retrieval, microwave treatment in distilled water for 10 min was performed, followed by washing in PBS for 5 min. Subsequently, the sections were incubated with primary antibody overnight at 41C. The sections were then washed three times in PBS and incubated with horseradish peroxidase (HRP)-conjugated anti-mouse antibody or anti-rabbit antibody for 30 min at room temperature. The sections were then washed three times in PBS and incubated at room temperature with 3,3diaminobenzidine (Dako, Glostrup, Denmark). All sections were counterstained with hematoxylin. We confirmed the staining specificity by replacing the primary antibodies with an appropriate amount of PBS.
In addition, we performed double staining on sections, including those from the hippocampus and the parahippocampal gyrus for further characterization. We applied the same primary antibodies as described above. These primary antibodies were detected with the following secondary antibodies (dilution 1 : 1000; Molecular Probes, Eugene, Oregon, USA): Alexa Fluor 488 donkey anti-rabbit IgG, and Alexa Fluor 568 donkey anti-gout or mouse IgG. We also used the method of tyramide signal amplification (TSA) with the same HRP-conjugated secondary antibodies as described above and the TSA kit #12: Alexa Fluor 488 donkey, TSA kit #4: Alexa Fluor 568 donkey (Invitrogen, Eugene, Oregon, USA). Before mounting the paraffinembedded sections, 0.5% (w/v) Sudan black in 70% (v/v) ethanol was used to quench autofluorescence. The slides were mounted with Vectashield (Vector Laboratories, Burlingame, California, USA) and observed under an LSM510 confocal laser scanning microscope (Carl Zeiss AG, Oberkochen, Germany).
Results
In Alzheimer's disease cases, CDK5-positive material was observed in granules formed in hippocampal neurons, particularly in the CA1 region ( Fig. 1a ). Most of the fine spherical granules stained homogenously, and were observed to accumulate in the perinuclear region of the soma of pyramidal neurons. In addition, neurofibrillary tangles, pretangles, and ghost tangles were also immunoreactive for CDK5 in pyramidal neurons. We confirmed the specificity of immunoreactivity using negative controls, which were incubated without the primary antibodies. The negative control showed no staining.
In MyD cases, fewer CDK5-positive granules were observed when compared with Alzheimer's disease cases. CDK5-positive granules were found in hippocampal neurons, particularly in the CA1 region, and the distribution pattern was similar to Alzheimer's disease cases (Fig. 1b) . In control cases, we could not detect any CDK5positive granules throughout the regions examined.
Of note, in Alzheimer's disease and MyD cases, some CDK5-positive granules were observed in 3-5-mmdiameter spherical vacuoles, which were surrounded by a halo-like clear zone [6, 19] . This characteristic appearance and distribution was reminiscent of granulovacuolar degeneration. We assessed whether CDK5 colocalized with pSmad2/3 or Ub or phospho-TDP-43, well known markers for granulovacuolar degeneration [19] [20] [21] using double immunofluorescent labeling. CDK5-positive granulovacuolar degeneration-like granules colocalized with pSmad2/3, Ub and phospho-TDP-43 in Alzheimer's disease, and MyD cases ( Fig. 1c-e ). These results suggest that these CDK5-positive granules correspond to the intraluminal granules of granulovacuolar degeneration. The cell numbers of CDK5-positive granulovacuolar degeneration and the stages of granulovacuolar degeneration [22] are shown in Table 1 .
As CDK5 is one of the tau kinases, we next attempted to investigate the relationship between CDK5 and phosphorylated tau immunohistochemically. We assessed the colocalization of CDK5-positive granules and AT8-positive phosphorylated tau using double immunofluorescent labeling. CDK5-positive granules and AT8-positive phosphorylated tau proteins colocalized in pyramidal neurons in Alzheimer's disease and MyD cases, but the degree of immunoreactivity varied in each neuron. Some pyramidal neurons showed intense CDK5 and moderate to negative AT8 immunoreactivity in the soma and processes, whereas other pyramidal neurons showed weak CDK5 Presence of CDK5 in granulovacuolar degeneration Nakamori et al. 869
immunoreactivity, but had clustered AT8 immunostaining that occupied between half and the entire cytoplasm. Further analysis restricted to the relationship between CDK5-positive granulovacuolar degeneration granules and AT8-positive phosphorylated tau proteins reveled similar results, because the number of CDK5-positive granulovacuolar degeneration granules and other fine CDK5-positive granules were in parallel ( Fig. 2a) . Moreover, because CHMP2B is a sensitive granulovacuolar degeneration marker, we also investigated the colocalization of CHMP2B-positive granulovacuolar degeneration granules and AT8-positive phosphorylated tau by double immunofluorescent labeling. Similar to CDK5 and AT8 immunostaining, neurons that showed weak immunoreactivity for CHMP2B stained intensely for AT8, and neurons that stained intensely for CHMP2B stained weakly for AT8 ( Fig. 2b ).
Discussion
This study showed the presence of CDK5-immunopositive granules in hippocampal pyramidal neurons in Alzheimer's disease and MyD cases in agreement with previous studies on Alzheimer's disease. Augustinack et al. [14] showed CDK5 immunoreactivity in pretangles and neurofibrillary tangles following fluorescence resonance energy transfer, and strong colocalization of CDK5 with AT8 in early stage neurofibrillary tangle formation. Pei et al. [15] studied CDK5 immunoreactivity in the cytoplasm of neurons in the hippocampus and found inverse immunoreactivity between CDK5 and AT8, which is consistent with our results. We also demonstrated CDK5-positive granules in hippocampal neurons in not only Alzheimer's disease cases but also MyD cases.
Although it has been reported that granulovacuolar degeneration granules are found within hippocampal pyramidal neurons in normal aged brains [23] , in our study, we could not detect any CDK5-positive granules in control cases. However, the control cases examined in this study were relatively young patients, which may be a reason no CDK5-positive granulovacuolar degeneration granules were detected.
In this study, a fraction of CDK5-positive granules were shown to be identical to granulovacuolar degeneration granules morphologically and immunohistologically. Although previous reports have observed CDK5 immunoreactivity in neurons from Alzheimer's disease tissue [14, 15] , we are unaware of any reports investigating CDK5 immunoreactivity of granulovacuolar degeneration granules. The C-8 antibody for CDK5 used in this study has been employed in previous studies [14, 15] . However, the difference in staining protocol may have influenced the results. Compared with previous studies, we did not perform the process of eliminating endogenous peroxidase activity in tissues with H 2 O 2 or methanol. However, we assessed and confirmed staining specificity by replacing the primary antibodies with an appropriate amount of PBS. Another reason why CDK5-immunopositivity for granulovacuolar degeneration granules has been overlooked may be due to the fact that intraluminal vesicles of granulovacuolar degeneration granules are not easy to distinguish from other similar CDK5-positive granules without double staining for CDK5 and other granulovacuolar degeneration maker proteins. In MyD cases, immunohistochemical analysis for CDK5 also demonstrated the presence of granulovacuolar degeneration granules. Granulovacuolar degeneration granules are not only an Alzheimer's disease-specific hallmark, but are also found in other conditions concomitant with tau pathologies. We previously reported that granulovacuolar degeneration granules appear in relation to hippocampal phosphorylated tau accumulation in variety of tauopathies, such as MyD, Pick's disease, and pantothenate kinase-associated neurodegeneration [9] . In this study, we investigated MyD cases as well as Alzheimer's disease cases and showed CDK5 immunoreactivity for granulovacuolar degeneration granules and neurofibrillary tangles in both conditions.
Ubiquitin-proteasome pathway-related proteins including ubiquitin-related [19, 20] , endosome-related, and autophagy lysosome-related proteins, such as CHMP2B and lysosome-associated membrane protein 1 [7, 8] , and pSmad2/3 TGFb signal-related protein are markers for granulovacuolar degeneration granules [24] . Moreover, it is reported that granulovacuolar degeneration-like granules are immunopositive for phospho-TDP-43 [21] . To date, a number of tau kinases, such as JNK and GSK3b, have been reported as markers of granulovacuolar degeneration granules [2] [3] [4] , and in this study, we added CDK5 to the list. It is likely that other tau kinases that have not yet been investigated may be components of granulovacuolar degeneration. In addition, many tau kinases exist in neurofibrillary tangles. These findings suggest a close association between granulovacuolar degeneration and neurofibrillary tangles.
We have reported the coexistence of granulovacuolar degeneration granules and phosphorylated tau [9] , but at cellular level, the number of granulovacuolar degeneration granules and the maturation of neurofibrillary tangles are inversely related. Pei et al. [15] categorized the pattern of CDK5 (antibody C-8)-immunopositivity and phosphorylated tau (antibody AT8)-immunopositivity in CA1 pyramidal neurons of the Alzheimer's disease hippocampus into three categories: (a) a mainly normal looking pattern, (b) accumulation of CDK5 immunoreactivity in the cytoplasm, with or without the deposition of AT8 immunoreactivity, (c) relatively weaker CDK5 and stronger AT8 immunoreactivity in the cytoplasm. Pei and colleagues reported that an apparent increase of CDK5 immunoreactivity was observed in pretangle neurons and in neurons bearing early stage neurofibrillary tangles, and that along with the maturation of neurofibrillary tangles, CDK5 immunoreactivity decreased. Our result is in agreement with their findings. In particular, we showed the inverse relationship between granulovacuolar degeneration granules and neurofibrillary tangles using CDK5 and CHMP2B as marker of granulovacuolar degeneration. These results are also indicative of the relationship between the formation of granulovacuolar degeneration granules and neurofibrillary tangles. Several lines of evidence have suggested that granulovacuolar degeneration granules appear within hippocampal pyramidal neurons when phosphorylated tau begins to aggregate into early stage neurofibrillary tangles [3, 25] . Together with the findings that tau kinases including CDK5 are components of granulovacuolar degeneration, these results suggest that granulovacuolar degeneration might be a site in which tau modification would take place.
Conclusion
CDK5 is another marker of granulovacuolar degeneration. Many kinds of tau kinases including CDK5 exist in granulovacuolar degeneration complexes, which imply that a series of processes participate in the formation of granulovacuolar degeneration granules as well as neurofibrillary tangles. These evidences provide another clue to the relationship between tau kinases, granulovacuolar degeneration granules and neuronal death in Alzheimer's disease, and non-Alzheimer's disease tauopathies. Further studies need to focus on CDK5 immunoactivity and the formation of neurofibrillary tangles and granulovacuolar degeneration granules, to suppress the progression of tau-related neurodegenerative diseases.
